However, in our case, we deemed rituximab more appropriate due to the presence of anti-FH autoantibodies, as suggested by Caravaca-Fontán et al,12 and considering its efficacy in IgG4-RD.13 This evidence concerns the gene FH and immunoglobulin G4-related sclerosing disease.